Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

GlobalData's clinical trial report, “Duchenne Muscular Dystrophy – Global Clinical Trials Review, 2026" provides an overview of Duchenne Muscular Dystrophy Clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of Report

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

FAQs

  • North America accounted for the highest number of Duchenne muscular dystrophy clinical trials as of January 2024.

  • The US conducted the highest number of Duchenne muscular dystrophy clinical trials as of January 2024.

  • As of January 2024, the company sponsor type conducted most of the Duchenne muscular dystrophy clinical trials.

  • A few of the leading sponsors of Duchenne muscular dystrophy clinical trials are Sarepta Therapeutics Inc, PTC Therapeutics Inc, BioMarin Pharmaceutical Inc, Nippon Shinyaku Co Ltd, and GSK plc, among others.

What our clients have to say

More Reports

View More Reports